Showing 1 - 5 of 5 Parkinson's Disease
A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson's Disease

Status: Open Not Enrolling

Investigator: Olga Waln

Study Coordinator: Yvonne Subhan

Phone: 346.238.9068

The purpose of the study is to assess the safety and tolerability of UCB0599 and to demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of disease progression over 12 and 18 months in participants diagnosed with ... Read more >

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's Disease

Status: Enrolling

Investigator: William Ondo

Study Coordinator: Nijah Russell

Phone: 346.238.2287

This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy. ... Read more >

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease (TEMPO-1 TRIAL)

Status: Enrolling

Investigator: William Ondo

Study Coordinator:

Phone:

The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD. ... Read more >

A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components

Status: Enrolling

Investigator: Olga Waln

Study Coordinator: Yvonne Subhan

Phone: 346.238.9068

This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with Parkinson's Disease. ... Read more >

A Study of Biological Markers for the Nervous and Immune Systems and Free Radical Mediated Processes in Amyotrophic Lateral Sclerosis (ALS)

Status: Enrolling

Investigator: Stanley Appel

Study Coordinator: Aramide Balogun

Phone: 713.441.6947

The purpose of this protocol is to develop and maintain a biospecimen bank comprised of blood, urine, CSF collected during diagnostic evaluations, tissue from biopsies and autopsies collected from patients with neurological disease and non-neu ... Read more >